Role of the EZH2 histone methyltransferase as a therapeutic target in cancer

Pharmacology and Therapeutics

Volumn 165, Issue , 2016, Pages 26-31

  Italiano, Antoine ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE H3; HISTONE METHYLTRANSFERASE; LYSINE; METHYLTRANSFERASE INHIBITOR; TRANSCRIPTION FACTOR EZH2; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; TUMOR MARKER;

CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; ENZYME INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84970023387     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.05.003     Document Type: Review

References (51)

1. Baker, T., Nerle, S1., Pritchard, J1., Zhao, B1., Rivera, V.M1., Garner, A1., Gonzalvez, F1., Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors. Oncotarget 6 (2015), 32646–32655.
2. Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E., Helin, K., EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22 (2003), 5323–5335.
3. Callegaro-Filho, D., Gershenson, D.M., Nick, A.M., Munsell, M.F., Ramirez, P.T., Eifel, P.J.,.. Schmeler, K.M., Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases. Gynecol Oncol, 2015 (In Press).
4. Coindre, J.M., Terrier, P., Guillou, L., et al. Predictive value of grade for metastasis development in the main histological types of adult soft tissue sarcomas. A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91 (2001), 1914–1926.
5. Eskander, R.N., Ji, T., Huynh, B., Wardeh, R., Randall, L.M., Hoang, B., Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 23 (2013), 997–1005.
6. Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., Ochiai, A., MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. Oncogene 30 (2011), 4118–4128.
7. Garapaty-Rao, S., Nasveschuk, C., Gagnon, A., Chan, E.Y., Sandy, P., Busby, J.,.. Trojer, P., Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol 20 (2013), 1329–1339.
8. Gibaja, V., Shen, F., Harari, J., Korn, J., Ruddy, D., Saenz-Vash, V.,.. Chan, H.M., Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors. Oncogene 35 (2016), 558–566.
9. Hasselblatt, M., Isken, S., Linge, A., et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 52 (2013), 185–190.
10. Italiano, A., Keilhack, H., Toulmonde, M., Coindre, J.M., Michot, J.M., Massard, C.,.. Ribrag, V., A phase 1 study of EPZ-6438 (E7438), an enhancer of zeste-homolog 2 (EZH2) inhibitor: preliminary activity in INI1-negative tumors. European cancer congress, 2015 (abstract 302).
11. Jelinic, P., Mueller, J.J., Olvera, N., Dao, F., Scott, S.N., Shah, R.,.. Levine, D.A., Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 46 (2014), 424–426.
12. Jiang, T., Wang, Y., Zhou, F., Gao, G., Ren, S., Zhou, C., Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis. Oncotarget, 2015, Dec 14.
13. Johnston, L.D., Knutson, S.K., Warholic, N.M., Klaus, C.R., Wigle, T.J., Iwanowicz, D.,.. Raimondi, A., EZH2 inhibitor EPZ-6438 synergizes with anti-lymphoma therapies in preclinical models 2012. 54th annual meeting American Society of Hematology, 2012 (Abstract 4416).
14. Kadoch, C., Crabtree, G.R., Reversible disruption of mSWI/SNF (BAF) complexes by the SS18–SSX oncogenic fusion in synovial sarcoma. Cell 153 (2013), 71–85.
15. Karanikolas, B.D., Figueiredo, M.L., Wu, L., Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res 7 (2009), 1456–1465.
16. Katona, B.W., Liu, Y., Ma, A., Jin, J., Hua, X., EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. Cancer Biol Ther 15:12 (2014), 1677–1687.
17. Keilhack, H., Kawano, S., Knutson, S.K., Warholic, N.M., Kubica, J., Kuznetsov, G.,.. Copeland, R.A., Preclinical evaluation of EZH2 inhibtiors in models of human synovial sarcoma. Connective tissue oncology society annual meeting, 2014.
18. Keilhack, H., Yokoi, A., Knutson, S.K., Wigle, T., Warholic, N., Kawano, S.,.. Kuntz, K.W., Preclinical characterization of E7438, a potent, selective inhibitor of protein methyltransferase EZH2 with robust antitumor activity against EZH2 mutated non-Hodgkin lymphoma xenografts in mice. 54th annual meeting American Society of Hematology, 2012 (Abstract 3712).
19. Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N.,.. Roberts, C.W., SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med, 2015 (In Press).
20. Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A.,.. Chinnaiyan, A.M., EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100 (2003), 11606–11611.
21. Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A.,.. Keilhack, H., Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 110 (2013), 7922–7927.
22. Koh, C.M., Iwata, T., Zheng, Q., Bethel, C., Yegnasubramanian, S., De Marzo, A.M., Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2 (2011), 669–683.
23. Le Loarer, F., Watson, S., Pierron, G., de Montpreville, V.T., Ballet, S., Firmin, N.,.. Tirode, F., SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 47 (2015), 1200–1205.
24. Lee, R.S., Stewart, C., Carter, S.L., et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 122 (2012), 2983–2988.
25. Lewis, J.J., Antonescu, C.R., Leung, D.H.Y., et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumours of the extremity. J Clin Oncol 18 (2000), 2087–2094.
26. Li, X., Gonzalez, M.E., Toy, K., Filzen, T., Merajver, S.D., Kleer, C.G., Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol 175 (2009), 1246–1254.
27. Lu, J., He, M.L., Wang, L., Chen, Y., Liu, X., Dong, Q.,.. Li, X.P., MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 71 (2011), 225–233.
28. Mallen-St Clair, J., Soydaner-Azeloglu, R., Lee, K.E., Taylor, L., Livanos, A., Pylayeva-Gupta, Y.,.. Bar-Sagi, D., EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 26 (2012), 439–444.
29. Margueron, R., Reinberg, D., The polycomb complex PRC2 and its mark in life. Nature 469 (2011, Jan 20), 343–349.
30. McCabe, M.T., Ott, H.M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G.S.,.. Creasy, C.L., EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492 (2012), 108–112.
31. Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R.,.. Marra, M.A., Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42 (2010), 181–185.
32. Nakagawa, S., Okabe, H., Sakamoto, Y., Hayashi, H., Hashimoto, D., Yokoyama, N.,.. Baba, H., Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol 20:Suppl. 3 (2013), S667–S675.
33. Pisters, P.W.T., Leung, D.H.Y., Woodruff, J., et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 14 (1996), 1679–1689.
34. Ribrag, V., Soria, J.C., Michot, J.M., Schmitt, A., Postel-Vinay, S., Bijou, F.,.. Italiano, A., Phase 1 study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2): preliminary safety and activity in relapsed or refractory non-Hodgkin lymphoma (NHL) patients. 57th annual meeting American Society of Hematology, 2015 (abstract 473).
35. Roy, D.M., Walsh, L.A., Chan, T.A., Driver mutations of cancer epigenomes. Protein Cell 5 (2014), 265–296.
36. Saramäki, O.R., Tammela, T.L., Martikainen, P.M., Vessella, R.L., Visakorpi, T., The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45 (2006), 639–645.
37. Shen, H., Laird, P.W., Interplay between the cancer genome and epigenome. Cell 153 (2013), 38–55.
38. Singer, S., Corson, J.M., Gonin, R., et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 219 (1994), 165–173.
39. Spillane, A.J., A'Hern, R., Judson, I.R., et al. Synovial sarcoma: a clinicopathologic, staging and prognostic assessment. J Clin Oncol 18 (2000), 3794–3803.
40. Stallcup, M.R., Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene 20 (2001), 3014–3020.
41. Strother, D., Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther 5 (2005), 907–915.
42. Tang, S.H., Huang, H.S., Wu, H.U., Tsai, Y.T., Chuang, M.J., Yu, C.P.,.. Cha, T.L., Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. Oncotarget 5 (2014), 10342–10355.
43. Tiffen, J.C., Gunatilake, D., Gallagher, S.J., Gowrishankar, K., Heinemann, A., Cullinane, C.,.. Hersey, P., Oncotarget 6 (2015), 27023–27036.
44. Trassard, M., Le Doussal, V., Hacene, K., et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 patients. J Clin Oncol 19 (2001), 525–534.
45. Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeq, B.,.. Chinnaiyan, A.M., Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322 (2008), 1695–1699.
46. Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G.,.. Chinnaiyan, A.M., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002), 624–629.
47. Versteege, I., Sevenet, N., Lange, J., et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394 (1998), 203–206.
48. Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J.,.. Roberts, C.W., Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18 (2010), 316–328.
49. Witkowski, L., Carrot-Zhang, J., Albrecht, S., Fahiminiya, S., Hamel, N., Tomiak, E.,.. Foulkes, W.D., Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 46 (2014), 438–443.
50. Yap, D.B., Chu, J., Berg, T., Schapira, M., Cheng, S.W., Moradian, A.,.. Aparicio, S.A., Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117 (2011), 2451–2459.
51. Zheng, F., Liao, Y.J., Cai, M.Y., Liu, Y.H., Liu, T.H., Chen, S.P.,.. Xie, D., The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 61 (2012), 278–289.